CEO Loeillot Olivier sold 3,832 shares of RGEN at $140.00 (-27.8% from 52-week high); stock now $124.40
Loeillot Olivier, CEO of Repligen, sold 3,832 shares at $140.00 on 2026-04-21, reducing holdings by 6.6% to 54,246 shares post-transaction. The sale occurred 27.8% below the 52-week high of $172.26, following a 25.9% decline over the prior 90 days. His cross-ticker track record shows 1 prior sell with a 100% well-timed rate (average 90d return -20.4%), and his prior RGEN sale on 2025-11-25 demonstrated the same pattern. The company reports strong fundamentals with annual revenue growth of 16.4%, $188.8M latest-quarter revenue, and $14.9M net income; however, the P/E of 92.15 remains elevated relative to recent price momentum. Current price of $124.40 indicates the stock has fallen further since the transaction, consistent with the insider's historical sell-timing pattern.
CEO Loeillot Olivier sold 7,041 shares of RGEN at $170.00 for $1.2M; holds 35.9K post-transaction.
CEO Loeillot Olivier sold 7,041 shares (7.0K shares) at $170.00, reducing his stake from 42,939 shares to 35,898 shares (a -16.4% reduction in holdings). The transaction occurred at a price near the 52-week high of $174.24, within 1.8% of that peak. REPLIGEN's fundamentals present a mixed picture: while recent quarterly revenue stands at $188,805,000.00 and the company generated $14,911,000.00 in net income last quarter, full-year profitability was negative and annual revenue growth was -0.7%. The elevated P/E of 5706.00 reflects the company's recent unprofitability on a full-year basis. The sale occurs amid strong 90-day momentum (+40.1%) and 30-day strength (+6.3%), yet the CEO's decision to reduce exposure by 16.4% of his holdings at near-peak valuation deserves attention given the company's deteriorating annual profitability metrics and negative revenue growth trajectory.
